📉 The Financial Deep Dive
The Numbers:
Solara Active Pharma Sciences Limited and TV Vision Limited have reported a catastrophic financial performance for the quarter and nine months ended December 31, 2025 (Q3 FY26 & 9M FY26). Standalone total income from operations witnessed a staggering year-on-year (YoY) decline of 91.9% in Q3 FY26, plummeting to just ₹48.00 Lakhs. For the nine-month period, the decline was 68.3% YoY, to ₹1399.63 Lakhs. The consolidated income picture, while less severe, is still deeply concerning, with a 38.9% YoY drop in Q3 FY26 to ₹594.17 Lakhs and a 17.1% YoY fall for 9M FY26 to ₹4415.98 Lakhs.
The Quality:
Net losses remain a dominant feature for both entities. The standalone net loss before and after tax for Q3 FY26 was ₹601.36 Lakhs. While this represents a 39.6% reduction in loss YoY, it stems from a near-total collapse in revenue. For the nine months, the standalone net loss expanded by 11.9% YoY to ₹2112.26 Lakhs. On a consolidated basis, the net loss for Q3 FY26 ballooned by 50.9% YoY to ₹995.33 Lakhs, though the 9M FY26 consolidated loss saw a 29.3% YoY reduction to ₹1886.45 Lakhs. Earnings Per Share (EPS) remained firmly in negative territory for both periods and across both standalone and consolidated statements.
The financial health is further eroded by severe balance sheet issues. Significant accumulated losses have led to negative reserves, a critical red flag indicating a substantial erosion of shareholder equity. The classification of the companies' accounts as non-performing assets (NPAs) by banks is a grave concern, signalling immediate liquidity and solvency issues. The fact that banks are not providing interest on term loans underscores the severity of the default risk.
The Grill:
While no explicit management call or analyst grill transcript is available, the reported figures and subsequent events speak volumes. The most alarming aspect is the identical nature of the financial results reported by two seemingly distinct entities, Solara Active Pharma Sciences Limited and TV Vision Limited. This raises serious questions about inter-company dealings, potential financial engineering, or a shared systemic issue that has crippled both simultaneously. The lack of clarity on how these identical, dire numbers emerged will be a key point of scrutiny for regulators and investors alike.
Risks & Outlook:
The outlook for both Solara Active Pharma Sciences and TV Vision Limited is extremely bleak. The immediate and most pressing risk is the National Company Law Tribunal (NCLT) petition filed by a creditor. The impact of this petition is currently unascertainable, but it could lead to insolvency proceedings, restructuring, or liquidation. The NPA classification and lack of interest servicing by banks further compound the liquidity crisis, severely limiting operational flexibility and access to further credit. Investors are advised to exercise extreme caution, as the going concern assumption for these companies is under severe doubt.